Effects of End-inspiratory Pause on Ventilation

NCT ID: NCT06692634

Last Updated: 2024-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-20

Study Completion Date

2024-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the effect of reducing tidal volume and respiratory rate together with an end-inspiratory pause setting on ventilatory efficiency and the distribution of inspired gas within the lungs in ARDS patients. The study will use non-invasive monitoring of respiratory function with volumetric capnography and tomography by electrical impedance to evaluate the physiologic function. The expected results include a significant reduction of mechanical energy delivered by mechanical ventilation, improved ventilatory efficiency, and generate more homogenous ventilation with the end-inspiratory pause.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Reduction of tidal volume (VT) to 6 mL/kg normalized to predicted body weight (PBW) and driving pressure limitation up to 15 cmH20 are essential ventilatory strategies that positively impact clinical outcomes of acute respiratory distress syndrome (ARDS) patients. Recently, mechanical power has also been linked to ventilator-induced lung injury (VILI) and associated with mortality, mainly due to its dynamic-elastic effects. However, despite using these low VT strategies, it is possible to develop VILI in moderate to severe ARDS patients, especially when driving pressure exceeds established safety limits for lung protection. In these situations, a VT less than 6 mL/kg-PBW is recommended, but an increase in respiratory rates (RR) is required to counteract the side effects of secondary hypercapnia (PaCO2 levels greater than 45 mmHg). In turn, the RR needed to achieve this target is at least 25 breaths/min, even if a mild degree of hypercapnia is often accepted. Yet, mechanical ventilator programming with higher RR per minute may promote lung tissue inflammation and could be associated with adverse outcomes in ARDS.

Thus, in ARDS is challenging to establish a combined strategy of tidal volume (VT) and respiratory rate RR reduction since its utmost problem is an increase in the partial pressure of carbon dioxide (PaCO2) and impairment of ventilatory efficiency, the magnitude of which is linked to the disease severity. For this reason, some non-invasive strategies are available to attenuate hypercapnia and improve the lung's ability to CO2 clearance. Among them, it is worth highlighting the end-inspiratory pause (EIP). This strategy has shown its usefulness in increasing CO2 clearance by improving the mean time given to inspired gas for distribution and diffusive mixing within the lungs. Nevertheless, the role of EIP as part of a protective ventilation strategy that combines the VT and RR reductions is unknown.

Therefore, we hypothesize that adding an end-inspiratory pause (EIP) improves CO2 expiration and that such an effect allows a decrease in the VT and RR for more lung-protective purposes. Thus, the main objective of this study is to evaluate the effects of an EIP on Bohr´s dead space (VDBohr/VT) and PaCO2 when combined with a VT and the RR reduction in ARDS. The secondary aim is to evaluate ventilatory strategy on air distribution and homogeneity by electrical impedance tomography.

Patient selection Patients ≥18 years of age with mild, moderate, and severe ARDS up to 5 days of mechanical ventilation. Patients must be under deep sedation and neuromuscular paralysis. Patients with hemodynamic instability, acute heart failure, previous chronic respiratory disease, and variations in oesophageal temperature higher than 0.5 °C in the last 2 hours will be excluded.

Baseline mechanical ventilation settings Mechanical ventilation at baseline will be programmed in volume-controlled mode with a Servo-i (Maquet, Solna, Sweden) and the following parameters: a VT of 7 ml/kg-PBW, an RR adjusted to ensure an arterial pH greater than 7.30 and no intrinsic positive end-expiratory pressure (PEEP), an inspiratory insufflation time of 0.6 seconds, an inspiratory: expiratory (I: E) ratio of 1:2, and no EIP. End-expiratory transpulmonary pressure will be set at the beginning of the study by electrical impedance tomography. The PBW was calculated as follows: 50+ \[0.91 \*(height in cm-152.4)\] for men and 45.5+ \[0.91\* (height in cm-152.4)\] for women. Active humidification will be used in all participants, and compressible volume compensation was performed in each mechanical ventilator used before starting the protocol.

Respiratory mechanics Airway pressure, esophageal pressure, and gas flow will be measured continuously by a proximal pneumotachograph (MBMED, Buenos Aires, Argentina). Data will be downloaded on a second laptop after proper flow and pressure sensors calibration. Respiratory driving pressure will be determined as plateau pressure minus total PEEP (PEEPTOT = external PEEP + intrinsic PEEP) and respiratory system compliance as Crs = VT/Pplat-PEEPTOT.

Respiratory mechanics were calculated offline using specific software, elastic-dynamic power was calculated according to Costa et al study, and minute ventilation was indexed by PBW.

Volumetric capnography Expired CO2 will be measured by an infrared mainstream sensor (Capnostat 5®; USA) and integrated into a monitor (MBMed CO2 Module). Volumetric capnograms were reconstructed automatically using MATLAB® (Natick, MA, USA), which allows ventilation analysis in volumetric capnograms using a mathematical algorithm that adjusts the tidal volume to the exhaled CO2. The following parameters were recorded: the airway dead space fraction (VDaw/VT), VDBohr/VT, index of gas exchange (VDEnghoff/VT), CO2 elimination per breath (VTCO2,br), alveolar minute ventilation, the fraction of expired CO2 (FECO2), minute elimination of CO2 (VTCO2,br \* RR), end-tidal CO2 and the mean alveolar partial pressure of CO2 (PACO2).

The capnogram at phase III (SIII) is normalized (SnIII) by the FECO2 of the corresponding expiratory cycle. SnIII allows a comparison of slopes from breaths with different CO2 excretion rates, which could be expected to occur during modifications in the setting of the VT or RR. Alveolar minute ventilation will be calculated using the formula: alveolar ventilation \* RR indexed by PBW. Ventilatory efficiency is defined as the relationship between alveolar ventilation per minute and minute ventilation.

The flow sensor is automatically adjusted to values recorded with the Body Temperature \& Pressure Saturated (BTPS) conversion factor to determine the exhaled air volume.

Electrical impedance tomography

A 16-electrode belt will be placed in the mid-thoracic region, and continuous lung impedance will be assessed by electrical impedance tomography (EIT) (Dräger Medical Systems, USA). Offline analysis of EIT data will be performed, and the following parameters were calculated:

* Lung inhomogeneity is determined by the global inhomogeneity index (GI), which quantifies the homogeneity of the tidal volume distribution through quantitative lung pixel impedance dispersion.
* Regional ventilation distribution is assessed by the impedance ratio (IR), a parameter for determining the dependent and non-dependent regions' air distribution. An IR \> 1 represents a ventral distribution predominance, while an IR \< 1 represents mainly a dorsal distribution. Briefly, the ventral region corresponds to regions of interest 1 and 2, and the dorsal region corresponds to regions of interest 3 and 4.
* Tidal variation of impedance (TVI) represents impedance change generated by inspired gas during a respiratory cycle.
* End-expiratory lung impedance (EELI) corresponds to the impedance value at the end of expiration.

Protocol All patients will be lying in a semi-recumbent position at 40 degrees, and before starting the study, a period of stabilization of 60 minutes must be mandated. PEEP and insufflation time settings will be kept constant throughout the study. For safety reasons, we predefined that the protocol could be stopped at any time in the event of significant alterations in systemic hemodynamics and/or respiratory acidosis (pH ≤ 7.25 and PaCO2 ≥ 60 mmHg).

The following data were collected at inclusion: demographic variables (age, sex, height), Acute Physiology, and Chronic.

Sequential protocol steps

* Step I: Tidal volume (VT) 7 ml/kg-PBW, with constant positive end-expiratory pressure (PEEP), respiratory rate (RR), and insufflation time (0.6 sec), without adding an end-inspiratory pause (EIP). inspiratory: expiratory (I: E) ratio of 1:2. 60 minutes long.
* Step II: VT 5 ml/kg-PBW with constant PEEP, RR, and insufflation time (0.6 sec) without adding an end-inspiratory pause (EIP). I:E ratio of 1:2. 60 minutes long.
* Step III: EIP will be configured to achieve an I:E ratio of 1:1, keeping constant the insufflation time at 0.6 sec and the VT at 5 ml/kg-PBW. PEEP and RR will not be changed from baseline conditions. 60 minutes long.
* Step IV: The RR will be reduced by 20%, keeping constant the VT in 5 ml/kg-PBW. The insufflation time will be maintained at 0.6 sec, and the I:E ratio was equal to 1:1; consequently, the EIP will be prolonged again. 60 minutes long.

Volumetric capnography will be recorded, and an offline analysis will be performed using the mean value of the last 40 breaths. Gas exchange measurements were also performed at the end of each phase using a conventional blood gas analyzer (GEM® 4000, Instrumentation Laboratory, Lexington, USA). Hemodynamic variables and pulse oximetry will be continuously monitored (Multiparameter Spacelabs 91393). To identify the influence of cardiac output variations on CO2 dynamics, minimally invasive cardiac output monitoring will be installed (Edwards Lifesciences, USA). If needed, a norepinephrine infusion will be used to maintain the mean arterial pressure near 65 mmHg, and no bolus of fluid was administered during the protocol.

Statistical analysis The Shapiro-Wilk test will be performed to determine the distribution of continuous variables, which will be expressed as mean, standard deviation, or median and interquartile range as appropriate. Friedman´s nonparametric test, the Wilcoxon matched-pairs signed-rank test, and Dunn's post hoc comparisons will be performed to compare multiple variables.

A two-tailed p-value less than 0.05 was considered statistically significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Distress Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Step I: VT 7 ml/kg-PBW, with constant PEEP, RR, and insufflation time (0.6 sec), without adding an EIP. I:E ratio 1:2.

Step II: VT 5 ml/kg-PBW keeping the other mechanical ventilation settings constant.

Step III: EIP will be configured to achieve an I:E ratio of 1:1, keeping the other mechanical ventilation settings constant.

Step IV: Patients will be randomized into two groups in a 1:1 ratio.

Group 1: 20% reduction in RR together with a new setting in EIP until reach I:E equal 1, without modifying the other mechanical ventilation settings.

Group 2: 20% reduction in RR without modifying the other mechanical ventilation settings. A modification of the I:E ratio will be generated concerning step III. After 60 minutes, a new EIP setting will be made until reaching an I:E ratio equal to 1.

All steps will have a 60-minute long. Both arms will have the same programming of the mechanical ventilator at the end of the study.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Reduce tidal volume from 7 ml/kg to 5 ml/kg. Set end-inspiratory pause. respiratory rate reduction until 20% of the basal condition, together with a new increase in end-inspiratory pause.

Group Type EXPERIMENTAL

mechanical ventilation setting

Intervention Type OTHER

VT reduction, EIP setting, RR reduction, and a new EIP programing.

Group 2

Reduce tidal volume from 7 ml/kg to 5 ml/kg. Set end-inspiratory pause. respiratory rate reduction until 20% of the basal condition, and after that, will be set a new increase in end-inspiratory pause.

Group Type EXPERIMENTAL

mechanical ventilation setting

Intervention Type OTHER

VT reduction, EIP setting, RR reduction, and a new EIP programing.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mechanical ventilation setting

VT reduction, EIP setting, RR reduction, and a new EIP programing.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ≥18 years of age with moderate and severe ARDS and up to 5 days of mechanical ventilation. Patients must be subjected to deep sedation and neuromuscular paralysis.

Exclusion Criteria

* Patients with hemodynamic instability, acute heart failure, previous chronic respiratory disease, and variations in oesophageal temperature higher than 0.5 °C in the last 2 hours were excluded
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinica las Condes, Chile

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martín Benites, MD

Role: PRINCIPAL_INVESTIGATOR

Clínica Las Condes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clínica Las Condes

Santiago, Santiago Metropolitan, Chile

Site Status

Martín Hernán Benites

Santiago, Santiago Metropolitan, Chile

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Chile

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Martín Benites, MD

Role: CONTACT

+56 9 59226347

References

Explore related publications, articles, or registry entries linked to this study.

Devaquet J, Jonson B, Niklason L, Si Larbi AG, Uttman L, Aboab J, Brochard L. Effects of inspiratory pause on CO2 elimination and arterial PCO2 in acute lung injury. J Appl Physiol (1985). 2008 Dec;105(6):1944-9. doi: 10.1152/japplphysiol.90682.2008. Epub 2008 Sep 18.

Reference Type BACKGROUND
PMID: 18801962 (View on PubMed)

Aguirre-Bermeo H, Moran I, Bottiroli M, Italiano S, Parrilla FJ, Plazolles E, Roche-Campo F, Mancebo J. End-inspiratory pause prolongation in acute respiratory distress syndrome patients: effects on gas exchange and mechanics. Ann Intensive Care. 2016 Dec;6(1):81. doi: 10.1186/s13613-016-0183-z. Epub 2016 Aug 24.

Reference Type BACKGROUND
PMID: 27558174 (View on PubMed)

Uttman L, Jonson B. A prolonged postinspiratory pause enhances CO2 elimination by reducing airway dead space. Clin Physiol Funct Imaging. 2003 Sep;23(5):252-6. doi: 10.1046/j.1475-097x.2003.00498.x.

Reference Type BACKGROUND
PMID: 12950321 (View on PubMed)

Aboab J, Niklason L, Uttman L, Brochard L, Jonson B. Dead space and CO(2) elimination related to pattern of inspiratory gas delivery in ARDS patients. Crit Care. 2012 Dec 12;16(2):R39. doi: 10.1186/cc11232.

Reference Type BACKGROUND
PMID: 22390777 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

O01102022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ventilator Mode and Respiratory Physiology
NCT06624254 ENROLLING_BY_INVITATION